Meta-Targeting

  This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 864121)  

Title

Macro-Nanomedicine to Treat Metastatic Cancer

Concept

The ultimate goal of the EU-funded Meta-Targeting project is to develop a novel, complex, nanomedicine-based approach that will improve the efficacy and decrease the side effects of treatment of metastatic breast cancer. The project's objective is to introduce multifunctional polymeric micelles co-loaded with three different drugs and with an imaging agent. In addition to the anti-tumour drug doxorubicin, the co-loading with the angiotensin receptor inhibitor losartan will help to improve the delivery of micelles. The co-loading with the P-glycoprotein inhibitor tariquidar will improve anti-tumour efficacy without typical side effects such as neurotoxicity. The imaging- and biopsy-based biomarkers are necessary for patient stratification, which is important for the clinical translation of cancer nanomedicines.

Additional information

This grant is hosted at the University Hospital RWTH Aachen (UKA).